Links to Exploration step
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Influence of Renal Replacement Modalities on Amikacin Population Pharmacokinetics in Critically Ill Patients on Continuous Renal Replacement Therapy</title><author><name sortKey="Roger, Claire" sort="Roger, Claire" uniqKey="Roger C" first="Claire" last="Roger">Claire Roger</name><affiliation><nlm:aff id="aff1">Service des Réanimations, Pôle Anesthésie Réanimation Douleur Urgence, CHU Nîmes, Nîmes, France</nlm:aff></affiliation><affiliation><nlm:aff id="aff2">Burns, Trauma, and Critical Care Research Centre, The University of Queensland, Brisbane, Queensland, Australia</nlm:aff></affiliation></author><author><name sortKey="Wallis, Steven C" sort="Wallis, Steven C" uniqKey="Wallis S" first="Steven C." last="Wallis">Steven C. Wallis</name><affiliation><nlm:aff id="aff2">Burns, Trauma, and Critical Care Research Centre, The University of Queensland, Brisbane, Queensland, Australia</nlm:aff></affiliation></author><author><name sortKey="Muller, Laurent" sort="Muller, Laurent" uniqKey="Muller L" first="Laurent" last="Muller">Laurent Muller</name><affiliation><nlm:aff id="aff1">Service des Réanimations, Pôle Anesthésie Réanimation Douleur Urgence, CHU Nîmes, Nîmes, France</nlm:aff></affiliation></author><author><name sortKey="Saissi, Gilbert" sort="Saissi, Gilbert" uniqKey="Saissi G" first="Gilbert" last="Saissi">Gilbert Saissi</name><affiliation><nlm:aff id="aff1">Service des Réanimations, Pôle Anesthésie Réanimation Douleur Urgence, CHU Nîmes, Nîmes, France</nlm:aff></affiliation></author><author><name sortKey="Lipman, Jeffrey" sort="Lipman, Jeffrey" uniqKey="Lipman J" first="Jeffrey" last="Lipman">Jeffrey Lipman</name><affiliation><nlm:aff id="aff2">Burns, Trauma, and Critical Care Research Centre, The University of Queensland, Brisbane, Queensland, Australia</nlm:aff></affiliation><affiliation><nlm:aff id="aff3">School of Pharmacy, The University of Queensland, Brisbane, Queensland, Australia</nlm:aff></affiliation><affiliation><nlm:aff id="aff4">Department of Intensive Care Medicine, Royal Brisbane and Womens' Hospital, Brisbane, Queensland, Australia</nlm:aff></affiliation></author><author><name sortKey="Lefrant, Jean Yves" sort="Lefrant, Jean Yves" uniqKey="Lefrant J" first="Jean-Yves" last="Lefrant">Jean-Yves Lefrant</name><affiliation><nlm:aff id="aff1">Service des Réanimations, Pôle Anesthésie Réanimation Douleur Urgence, CHU Nîmes, Nîmes, France</nlm:aff></affiliation></author><author><name sortKey="Roberts, Jason A" sort="Roberts, Jason A" uniqKey="Roberts J" first="Jason A." last="Roberts">Jason A. Roberts</name><affiliation><nlm:aff id="aff2">Burns, Trauma, and Critical Care Research Centre, The University of Queensland, Brisbane, Queensland, Australia</nlm:aff></affiliation><affiliation><nlm:aff id="aff3">School of Pharmacy, The University of Queensland, Brisbane, Queensland, Australia</nlm:aff></affiliation><affiliation><nlm:aff id="aff4">Department of Intensive Care Medicine, Royal Brisbane and Womens' Hospital, Brisbane, Queensland, Australia</nlm:aff></affiliation><affiliation><nlm:aff id="aff5">Pharmacy Department, Royal Brisbane and Womens' Hospital, Brisbane, Queensland, Australia</nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">27270279</idno><idno type="pmc">4958154</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4958154</idno><idno type="RBID">PMC:4958154</idno><idno type="doi">10.1128/AAC.00828-16</idno><date when="2016">2016</date><idno type="wicri:Area/Pmc/Corpus">000433</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000433</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Influence of Renal Replacement Modalities on Amikacin Population Pharmacokinetics in Critically Ill Patients on Continuous Renal Replacement Therapy</title><author><name sortKey="Roger, Claire" sort="Roger, Claire" uniqKey="Roger C" first="Claire" last="Roger">Claire Roger</name><affiliation><nlm:aff id="aff1">Service des Réanimations, Pôle Anesthésie Réanimation Douleur Urgence, CHU Nîmes, Nîmes, France</nlm:aff></affiliation><affiliation><nlm:aff id="aff2">Burns, Trauma, and Critical Care Research Centre, The University of Queensland, Brisbane, Queensland, Australia</nlm:aff></affiliation></author><author><name sortKey="Wallis, Steven C" sort="Wallis, Steven C" uniqKey="Wallis S" first="Steven C." last="Wallis">Steven C. Wallis</name><affiliation><nlm:aff id="aff2">Burns, Trauma, and Critical Care Research Centre, The University of Queensland, Brisbane, Queensland, Australia</nlm:aff></affiliation></author><author><name sortKey="Muller, Laurent" sort="Muller, Laurent" uniqKey="Muller L" first="Laurent" last="Muller">Laurent Muller</name><affiliation><nlm:aff id="aff1">Service des Réanimations, Pôle Anesthésie Réanimation Douleur Urgence, CHU Nîmes, Nîmes, France</nlm:aff></affiliation></author><author><name sortKey="Saissi, Gilbert" sort="Saissi, Gilbert" uniqKey="Saissi G" first="Gilbert" last="Saissi">Gilbert Saissi</name><affiliation><nlm:aff id="aff1">Service des Réanimations, Pôle Anesthésie Réanimation Douleur Urgence, CHU Nîmes, Nîmes, France</nlm:aff></affiliation></author><author><name sortKey="Lipman, Jeffrey" sort="Lipman, Jeffrey" uniqKey="Lipman J" first="Jeffrey" last="Lipman">Jeffrey Lipman</name><affiliation><nlm:aff id="aff2">Burns, Trauma, and Critical Care Research Centre, The University of Queensland, Brisbane, Queensland, Australia</nlm:aff></affiliation><affiliation><nlm:aff id="aff3">School of Pharmacy, The University of Queensland, Brisbane, Queensland, Australia</nlm:aff></affiliation><affiliation><nlm:aff id="aff4">Department of Intensive Care Medicine, Royal Brisbane and Womens' Hospital, Brisbane, Queensland, Australia</nlm:aff></affiliation></author><author><name sortKey="Lefrant, Jean Yves" sort="Lefrant, Jean Yves" uniqKey="Lefrant J" first="Jean-Yves" last="Lefrant">Jean-Yves Lefrant</name><affiliation><nlm:aff id="aff1">Service des Réanimations, Pôle Anesthésie Réanimation Douleur Urgence, CHU Nîmes, Nîmes, France</nlm:aff></affiliation></author><author><name sortKey="Roberts, Jason A" sort="Roberts, Jason A" uniqKey="Roberts J" first="Jason A." last="Roberts">Jason A. Roberts</name><affiliation><nlm:aff id="aff2">Burns, Trauma, and Critical Care Research Centre, The University of Queensland, Brisbane, Queensland, Australia</nlm:aff></affiliation><affiliation><nlm:aff id="aff3">School of Pharmacy, The University of Queensland, Brisbane, Queensland, Australia</nlm:aff></affiliation><affiliation><nlm:aff id="aff4">Department of Intensive Care Medicine, Royal Brisbane and Womens' Hospital, Brisbane, Queensland, Australia</nlm:aff></affiliation><affiliation><nlm:aff id="aff5">Pharmacy Department, Royal Brisbane and Womens' Hospital, Brisbane, Queensland, Australia</nlm:aff></affiliation></author></analytic><series><title level="j">Antimicrobial Agents and Chemotherapy</title><idno type="ISSN">0066-4804</idno><idno type="eISSN">1098-6596</idno><imprint><date when="2016">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p>The objective of this study was to describe amikacin pharmacokinetics (PK) in critically ill patients receiving equal doses (30 ml/kg of body weight/h) of continuous venovenous hemofiltration (CVVH) and continuous venovenous hemodiafiltration (CVVHDF). Patients receiving amikacin and undergoing CVVH or CVVHDF were eligible. Population pharmacokinetic analysis and Monte Carlo simulation were undertaken using the Pmetrics software package for R. Sixteen patients (9 undergoing CVVH, 11 undergoing CVVHDF) and 20 sampling intervals were analyzed. A two-compartment linear model best described the data. Patient weight was the only covariate that was associated with drug clearance. The mean ± standard deviation parameter estimates were 25.2 ± 17.3 liters for the central volume, 0.89 ± 1.17 h<sup>−1</sup> for the rate constant for the drug distribution from the central to the peripheral compartment, 2.38 ± 6.60 h<sup>−1</sup> for the rate constant for the drug distribution from the peripheral to the central compartment, 4.45 ± 2.35 liters/h for hemodiafiltration clearance, and 4.69 ± 2.42 liters/h for hemofiltration clearance. Dosing simulations for amikacin supported the use of high dosing regimens (≥25 mg/kg) and extended intervals (36 to 48 h) for most patients when considering PK/pharmacodynamic (PD) targets of a maximum concentration in plasma (<italic>C</italic><sub>max</sub>)/MIC ratio of ≥8 and a minimal concentration of ≤2.5 mg/liter at the end of the dosing interval. The mean clearance of amikacin was 1.8 ± 1.3 liters/h by CVVHDF and 1.3 ± 1 liters/h by CVVH. On the basis of simulations, a strategy of an extended-interval high loading dose of amikacin (25 mg/kg every 48 h) associated with therapeutic drug monitoring (TDM) should be the preferred approach for aminoglycoside treatment in critically ill patients receiving continuous renal replacement therapy (CRRT). (This study is a substudy of a trial registered at ClinicalTrials.gov under number NCT01403220.)</p></div></front></TEI><pmc article-type="research-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Antimicrob Agents Chemother</journal-id><journal-id journal-id-type="iso-abbrev">Antimicrob. Agents Chemother</journal-id><journal-id journal-id-type="hwp">aac</journal-id><journal-id journal-id-type="pmc">aac</journal-id><journal-id journal-id-type="publisher-id">AAC</journal-id><journal-title-group><journal-title>Antimicrobial Agents and Chemotherapy</journal-title></journal-title-group><issn pub-type="ppub">0066-4804</issn><issn pub-type="epub">1098-6596</issn><publisher><publisher-name>American Society for Microbiology</publisher-name><publisher-loc>1752 N St., N.W., Washington, DC</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27270279</article-id><article-id pub-id-type="pmc">4958154</article-id><article-id pub-id-type="publisher-id">00828-16</article-id><article-id pub-id-type="doi">10.1128/AAC.00828-16</article-id><article-categories><subj-group subj-group-type="heading"><subject>Pharmacology</subject></subj-group></article-categories><title-group><article-title>Influence of Renal Replacement Modalities on Amikacin Population Pharmacokinetics in Critically Ill Patients on Continuous Renal Replacement Therapy</article-title><alt-title alt-title-type="running-head">PK/PD of Amikacin in Critically Ill Patients on RRT</alt-title><alt-title alt-title-type="short-authors">Roger et al.</alt-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Roger</surname><given-names>Claire</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref><xref ref-type="aff" rid="aff2"><sup>b</sup></xref></contrib><contrib contrib-type="author"><name><surname>Wallis</surname><given-names>Steven C.</given-names></name><xref ref-type="aff" rid="aff2"><sup>b</sup></xref></contrib><contrib contrib-type="author"><name><surname>Muller</surname><given-names>Laurent</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Saissi</surname><given-names>Gilbert</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Lipman</surname><given-names>Jeffrey</given-names></name><xref ref-type="aff" rid="aff2"><sup>b</sup></xref><xref ref-type="aff" rid="aff3"><sup>c</sup></xref><xref ref-type="aff" rid="aff4"><sup>d</sup></xref></contrib><contrib contrib-type="author"><name><surname>Lefrant</surname><given-names>Jean-Yves</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Roberts</surname><given-names>Jason A.</given-names></name><xref ref-type="aff" rid="aff2"><sup>b</sup></xref><xref ref-type="aff" rid="aff3"><sup>c</sup></xref><xref ref-type="aff" rid="aff4"><sup>d</sup></xref><xref ref-type="aff" rid="aff5"><sup>e</sup></xref></contrib><aff id="aff1"><label>a</label>Service des Réanimations, Pôle Anesthésie Réanimation Douleur Urgence, CHU Nîmes, Nîmes, France</aff><aff id="aff2"><label>b</label>Burns, Trauma, and Critical Care Research Centre, The University of Queensland, Brisbane, Queensland, Australia</aff><aff id="aff3"><label>c</label>School of Pharmacy, The University of Queensland, Brisbane, Queensland, Australia</aff><aff id="aff4"><label>d</label>Department of Intensive Care Medicine, Royal Brisbane and Womens' Hospital, Brisbane, Queensland, Australia</aff><aff id="aff5"><label>e</label>Pharmacy Department, Royal Brisbane and Womens' Hospital, Brisbane, Queensland, Australia</aff></contrib-group><author-notes><corresp id="cor1">Address correspondence to Claire Roger, <email>claire.roger@chu-nimes.fr</email>.</corresp><fn fn-type="other"><p><bold>Citation</bold> Roger C, Wallis SC, Muller L, Saissi G, Lipman J, Lefrant J-Y, Roberts JA. 2016. Influence of renal replacement modalities on amikacin population pharmacokinetics in critically ill patients on continuous renal replacement therapy. Antimicrob Agents Chemother 60:4901–4909. doi:<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1128/AAC.00828-16">10.1128/AAC.00828-16</ext-link>.</p></fn></author-notes><pub-date pub-type="epreprint"><day>6</day><month>6</month><year>2016</year></pub-date><pub-date pub-type="epub"><day>22</day><month>7</month><year>2016</year></pub-date><pub-date pub-type="collection"><month>8</month><year>2016</year></pub-date><volume>60</volume><issue>8</issue><fpage>4901</fpage><lpage>4909</lpage><history><date date-type="received"><day>14</day><month>4</month><year>2016</year></date><date date-type="rev-request"><day>15</day><month>5</month><year>2016</year></date><date date-type="accepted"><day>27</day><month>5</month><year>2016</year></date></history><permissions><copyright-statement>Copyright © 2016, American Society for Microbiology. All Rights Reserved.</copyright-statement><copyright-year>2016</copyright-year><copyright-holder>American Society for Microbiology</copyright-holder></permissions><self-uri content-type="pdf" xlink:href="zac00816004901.pdf"></self-uri><abstract><p>The objective of this study was to describe amikacin pharmacokinetics (PK) in critically ill patients receiving equal doses (30 ml/kg of body weight/h) of continuous venovenous hemofiltration (CVVH) and continuous venovenous hemodiafiltration (CVVHDF). Patients receiving amikacin and undergoing CVVH or CVVHDF were eligible. Population pharmacokinetic analysis and Monte Carlo simulation were undertaken using the Pmetrics software package for R. Sixteen patients (9 undergoing CVVH, 11 undergoing CVVHDF) and 20 sampling intervals were analyzed. A two-compartment linear model best described the data. Patient weight was the only covariate that was associated with drug clearance. The mean ± standard deviation parameter estimates were 25.2 ± 17.3 liters for the central volume, 0.89 ± 1.17 h<sup>−1</sup> for the rate constant for the drug distribution from the central to the peripheral compartment, 2.38 ± 6.60 h<sup>−1</sup> for the rate constant for the drug distribution from the peripheral to the central compartment, 4.45 ± 2.35 liters/h for hemodiafiltration clearance, and 4.69 ± 2.42 liters/h for hemofiltration clearance. Dosing simulations for amikacin supported the use of high dosing regimens (≥25 mg/kg) and extended intervals (36 to 48 h) for most patients when considering PK/pharmacodynamic (PD) targets of a maximum concentration in plasma (<italic>C</italic><sub>max</sub>)/MIC ratio of ≥8 and a minimal concentration of ≤2.5 mg/liter at the end of the dosing interval. The mean clearance of amikacin was 1.8 ± 1.3 liters/h by CVVHDF and 1.3 ± 1 liters/h by CVVH. On the basis of simulations, a strategy of an extended-interval high loading dose of amikacin (25 mg/kg every 48 h) associated with therapeutic drug monitoring (TDM) should be the preferred approach for aminoglycoside treatment in critically ill patients receiving continuous renal replacement therapy (CRRT). (This study is a substudy of a trial registered at ClinicalTrials.gov under number NCT01403220.)</p></abstract><funding-group><award-group id="award1"><funding-source id="gs1">Department of Health | National Health and Medical Research Council (NHMRC)
<named-content content-type="funder-id">http://dx.doi.org/10.13039/501100000925</named-content></funding-source><award-id rid="gs1">APP1048652</award-id><principal-award-recipient>Jason A. Roberts</principal-award-recipient></award-group><funding-statement>This work was supported by an academic grant from the Nîmes University Hospital.</funding-statement></funding-group><counts><fig-count count="4"></fig-count><table-count count="4"></table-count><equation-count count="0"></equation-count><ref-count count="34"></ref-count><page-count count="9"></page-count><word-count count="7038"></word-count></counts></article-meta></front></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000433 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 000433 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé=
|texte=
}}
| This area was generated with Dilib version V0.6.33. |  |